Artificial Intelligence-based Parkinson's Disease Risk Assessment (AI-PRA) Study

ClinicalTrials.gov ID

NCT07706829

Lead Sponsor

Queen Mary University of LondonOTHER

Overall Status

Not yet recruiting

Study Type

Observational

Enrollment

60Estimated

Last Update Posted

Jul 20, 2026Actual

Start Date

Jul 1, 2026Estimated

Primary Completion Date

Sep 30, 2027Estimated

Completion Date

Sep 30, 2027Estimated

Official Title

Artificial Intelligence-based Parkinson's Disease Risk Assessment (AI-PRA) Study

Brief Summary

The study aims to provide initial proof-of-concept validation data of an artificial intelligence-based model to estimate individual Parkinson's disease risk using demographic, clinical, genetic information and digital biomarker data collected via a smartwatch and a mobile application.

Detailed Description

Background: Everyday electronic devices may detect subtle motor and non-motor abnormalities years before the clinical diagnosis of Parkinson's disease (PD) providing opportunities for early detection.

Study aim and impact: This study aims to validate an artificial intelligence based model that provides an individualised risk of PD based on demographic, clinical, genetic and digital biomarker data (smartwatch and a phone app). An early diagnosis will allow timely interventions to manage symptoms and risk stratification of participants for early clinical trials.

Methods: 60 people at risk of PD (either with polysomnography confirmed REM sleep behaviour disorder; OR neurogenic orthostatic hypotension; OR objective hyposmia on smell test) will be recruited.

Participants will complete study assessments to provide PD risk estimation using current research clinical criteria and the artificial intelligence model. Study assessments will include:

• In-person visits (baseline and 6 months) to complete validated questionnaires and a neurological examination (including cognitive and motor assessments).
• Brain dopamine (DAT) scan (baseline only).
• blood tests for PD polygenic risk score (baseline only) and plasma urate (in males only at baseline and 6 months).
• Smartwatch and phone app: a smartwatch linked to the participants' smartphone will provide digital biomarker and additional clinical information through questionnaires via study phone app.

An artificial intelligence based model (AI-PROGNOSIS model) will use these digital data in combination with demographics, clinical and genetic information to provide an individualised PD risk estimation.

Accuracy measures of the risk estimates from the current research diagnostic criteria and artificial intelligence model using the presence of abnormal dopamine DAT scan as the ground truth for PD diagnosis will be provided.

• Parkinson Disease (PD)
• REM Sleep Behavior Disorder (iRBD)
• Neurogenic Orthostatic Hypotension
• Hyposmia

• Smartwatch and phone app

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

1. Age ≥ 50 years.

2. At least one of the following clinical markers for PD risk:

   1. REM sleep behaviour disorder (RBD) confirmed with polysomnography.
   2. Neurogenic orthostatic hypotension (nOH) defined as a drop in systolic / diastolic blood pressure ≥ 20/10mmHg within 3 minutes of active standing or tilt-table test, and with a blunted heart rate response (ΔHeart rate/ΔSBP ratio < 0.5 bpm/mmHg).
   3. Objective hyposmia defined as University of Pennsylvania Smell Identification Test (UPSIT) score ≤ 15th percentile for age and sex.

3. Able and willing to give informed written consent.

4. Use of compatible smartphone (mobile operating system Android version 11 or newer). A smartwatch will be provided to each participant for the duration of the study.

Exclusion Criteria:

1. Clinical diagnosis of Parkinson's disease (PD) according to MDS clinical diagnostic criteria.
2. Currently taking levodopa, dopamine agonists, MAO-B inhibitors, amantadine or another PD medication, except for low-dose treatment of restless leg syndrome (with permission of investigator).
3. Dementia defined as deterioration of cognitive function severe enough to impair functioning on daily activities.
4. Active treatment with neuroleptics, reserpine or metoclopramide (these drugs should be discontinued for at least 6 months before screening visit) due to their interference with dopamine transporter SPECT imaging acquisition and interpretation.
5. Pregnant women.
6. Concomitant participation in interventional studies.
7. Unwilling or unable to give informed written consent.
8. Vulnerable individuals as defined by the HRA.
9. Inability to use the smartwatch and/or the mAI-Health app for the purpose of the study as judged by the investigator.

Observational Model

Cohort

Time Perspective

Prospective

Lead Sponsor

Queen Mary University of LondonOTHER

Collaborators

Hospital Ruber InternacionalOTHER

University Hospital, ToulouseOTHER

Aristotle University Of ThessalonikiOTHER

mkurtis@ruberinternacional.es+34913875000

e.depablofernandez@qmul.ac.uk+44 20 7882 8693

• AI-PROGNOSIS - Digital Biomarkers Development Study (dBM-DEV)

  NCT06444789

  Unknown statusObservationalUpdated Aug 27, 2024
• AI-based Progression and Medication Response Prediction Study in Parkinson's Disease

  NCT07189468

  Not yet recruitingObservationalUpdated Sep 24, 2025
• Real-PD Trial: Development of Clinical Prognostic Models for Parkinson's Disease

  NCT02474329

  CompletedObservationalUpdated Dec 6, 2021
• Artificial Intelligence in Molecular Imaging: Predicting Parkinson's Risk in REM Sleep Behavior Disorder

  NCT06629207

  RecruitingInterventionalNot ApplicableUpdated Nov 8, 2024
• Predicting Parkinson's Disease Before It Strikes: A Brain Imaging Study in At-Risk Individual

  NCT07729748

  Active, not recruitingObservationalUpdated Jul 28, 2026
• DTx Algorithms for Personalized Parkinson's Disease Treatment and Medication Plan Optimization

  NCT05904288

  CompletedObservationalUpdated Sep 10, 2026